Ftsv has 78 percent owner ship of what Institute?
Post# of 148185
Quote:
Ftsv has 78 percent owner ship of what Institute?
Who is ftsv ?
Who is bp ?
FTSV is a prerevenue nasdaq company out of Stanford developing Magrolimab for cancer indications by blocking cd47, which is expressed on cells and heavily in cancer to tell macrophages don’t eat the cell. From what I can tell they only have one trial, phase 1B/2 that started in 2016. They just announced great results last year in that trial and their market cap was 200M in October and now have quickly accelerated 10x, now maybe 15x times since after that offer from Gilead yesterday. The started out of Standford with several MDs, PhD founding the company and several more on the bod, with those connections and being on Nasdaq they got a lot of institutional funding to fund the trials.
BP is short for Big Pharma, meaning the big pharmaceutical companies. People ask why BP hasn’t noticed CytoDyn like say FTSV. Well with HIV, I am willing to bet BP offered their standard 20% offer, and Cydy walked, meaning BP gets 80%, you get 20%. With cancer, FTSV is 4 years into their cancer trial with great results coming out now.
Just to show their are doubters in every stock, everywhere from Stocktwits recently
2 days ago
$FTSV lower intra-day highs suggest top as well as turning point, soon to be followed by lower lows. Insane and unmerited valuation at current stock price
4 days ago
$FTSV So overextended with a company losing 110MM per year. Definitely deserved to be above 15 after news, but not 50. Expecting a correction soon to 35. This manic approach to buying stocks is a fool's game